Clinical trial NCT03229798 - References

Migraine Disorders — Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002)

Citation(s)

•   Kam KR, Walsh LA, Bock SM, Koval M, Fischer KE, Ross RF, Desai TA
  Nanostructure-mediated transport of biologics across epithelial tissue: enhancing permeability via nanotopography. Nano Lett. 2013 Jan 9;13(1):164-71. doi: 10.1021/nl3037799. Epub 2012 Dec 24.
•   Owen K, Hartley K, Tucker ML, Parkinson MM, Tweats DJ, Jackson MR
  The preclinical toxicological evaluation of sumatriptan. Hum Exp Toxicol. 1995 Dec;14(12):959-73.
•   Walsh L, Ryu J, Bock S, Koval M, Mauro T, Ross R, Desai T
  Nanotopography facilitates in vivo transdermal delivery of high molecular weight therapeutics through an integrin-dependent mechanism. Nano Lett. 2015 Apr 8;15(4):2434-41. doi: 10.1021/nl504829f. Epub 2015 Mar 27.

An Open-Label Phase 1 Study to Establish the Pharmacokinetics and Safety of Sumatriptan Succinate Administered Via the Sofusa™ DoseConnect™ System at Escalating Doses Compared to Oral Imitrex® Single 100 mg Dose in Healthy Subjects

Details for clinical trial NCT03229798